You are here: Industry Insights > Soligenix

News List

Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine prnewswire
December 03, 2021
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need...
Thermostable Vaccine Technology Platform to be Presented at the 6th International Conference on Vaccines Research and Development prnewswire
November 02, 2021
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need...
Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates prnewswire
October 13, 2021
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need...
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development prnewswire
December 29, 2020
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that the National Institute of Allergy and Infectious Diseases (NIAID) ...
Soligenix Demonstrates Extended Protection with RiVax Ricin Toxin Vaccine americanpharmaceuticalreview
December 28, 2020
Soligenix has demonstrated extended protection with its heat stable ricin toxin vaccine, RiVax®. Mice, vaccinated twice on Days 1 and 21 were protected for at least 365 days against subsequent ricin challenge.
Soligenix Announces SGX301Study Continues to Demonstrate Positive Benefits americanpharmaceuticalreview
October 29, 2020
Soligenix announced continued optional treatment with SGX301 (synthetic hypericin) across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses..
Soligenix Licenses BTG’s CoVaccine HT for SARS-CoV-2 contractpharma
April 17, 2020
Novel adjuvant has been shown to enhance both cell-mediated and antibody-mediated immunity.
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine americanpharmaceuticalreview
December 17, 2019
Soligenix has opened the study titled "A Phase 1C, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety of RiVax® ...
Soligenix Announces NIH Small Business Innovation Research Award americanpharmaceuticalreview
August 16, 2019
Soligenix announced the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH), has awarded Soligenix a Phase I Small Business Innovation Research (SBIR) of
Soligenix Receives Patent for Improved Production of Synthetic Hypericin americanpharmaceuticalreview
August 24, 2018
Soligenix announced the United States Patent Office (USPTO) has granted the patent titled "Systems and Methods for Producing Synthetic Hypericin.”

Previous page 1 2 Next page